ArticleJournal of ovarian research2026
Identification of DHX58 as a potential therapeutic target for ovarian cancer through multi-omics Mendelian randomization and transcriptomic data analysis.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOvarian cancer (OC), a prevalent malignancy of the female reproductive system, is significantly impacted by drug resistance, which reduces treatment efficacy and worsens patient survival. Therefore, identifying broader therapeutic targets is crucial for improving treatment outcomes in OC patients.
methodsThe research project utilized Mendelian randomization (MR) analysis and summary data-based Mendelian randomization (SMR) to identity potential treatment targets for OC. The eQTLGen collaboration provided the cis-expression quantitative trait locus data, while the Genotype-Tissue Expression (GTEx) project v8 provided the ovarian tissue eQTL data. Protein quantitative trait locus (pQTL) was generated by the INTERVAL, Fenland, and SCALLOP studies. The open-access genome-wide association study (ID: GCST90018888), involving a European population, provided the summary statistics for OC. Additionally, colocalization analyses were employed to determine wether the same SNPs drive the expression of genes and OC risk, and transcriptomic and Single-cell RNA sequencing data analysis was utilized to further investigate the targets clinical significance of these in OC. To evaluate its potential for drug development, drug prediction and molecular docking analyses were also carried out.
resultsIn the SMR analysis, DHX58 was significantly associated with all three omics levels. The MR results indicated a correlation between elevated OC risk and DHX58 (OR = 1.300; 95% CI = 1.120–1.510; P = 0.000). Colocalization analysis further supported this finding (PP.H4 = 0.949). Our results revealed that DHX58 expression was significantly associated with patient prognosis, enriched immune-related pathways, and distinct immune cell infiltration patterns. PheWAS at the gene level revealed no significant correlation between DHX58 and additional phenotypes. The molecular docking results revealed strong interactions between DHX58 and other drugs and proteins with known structural information.
conclusionThis study confirmed a significant correlation between DHX58 and OC, indicating that DHX58 could be a viable target for OC treatment. Drugs targeting DHX58 are likely to have higher success rates in clinical trials, providing new directions for future clinical and basic research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.